About
Ternary Therapeutics is a London-based BioTech startup focused on developing a novel platform that combines physics-informed AI with rapid experimental validation to intentionally engineer molecular glues. Molecular glues are a new class of medicines capable of targeting proteins previously considered undruggable. The company's platform aims to move beyond the historical serendipitous discovery of molecular glues, treating drug discovery as an engineering problem.
Key facts
At-a-glance profile data
- Website
- ternarytx.co.uk
- Headquarters
- London, United Kingdom
- Founded
- 2024
- Total funding
- $4M (Seed)
- Business model
- B2B
Funding rounds
Tech stack
Detected on ternarytx.co.uk, last scanned 19 Sept 2026. Run your own scan
- Frontend
- Bootstrap
- CDN
- AWS CloudFront
- Hosting
- AWS
- Email provider
- Google Workspace
Frequently asked
What does Ternary Therapeutics do?
This approach allows for the predictable design and scaling of these molecules, expanding the range of druggable targets and opening new therapeutic avenues, particularly for inflammatory and neuroinflammatory diseases.
How much funding has Ternary Therapeutics raised?
Ternary Therapeutics has raised a total of $4M in funding. The most recent round on record is Seed.